— Know what they know.
Not Investment Advice

ZVRA NASDAQ

Zevra Therapeutics, Inc.
1W: -10.0% 1M: +0.0% 3M: +19.2% YTD: +25.8% 1Y: +21.8% 3Y: +124.6% 5Y: +15.2%
$10.03
-0.46 (-4.39%)
 
Weekly Expected Move ±7.5%
$9 $10 $11 $12 $13
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 51 · $592.9M mcap · 55M float · 2.25% daily turnover · Short 55% of daily vol

Cash Flow Trends

Operating Cash Flow
-$2M +97.7% ▲
Capital Expenditures
$835K +0.0% ▲
5Y CAGR: +90.8%
Free Cash Flow
-$2M +96.5% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$29M +408.9% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$9M-$42M-$46M-$106M$83M
Depreciation & Amort.$257K$944K$1M$6M$4M
Stock-Based Comp.$2M$4M$6M$15M$13M
Change in Working Capital-$357K-$406K$6M-$7M-$27M
Other Non-Cash Items$460K$18M-$329K$6M-$78M
Operating Cash Flow$10M-$19M-$34M-$70M-$2M
— Investing Activities —
Capital Expenditures-$102K-$93K-$296K$0-$835K
Acquisitions (Net)$0-$14M-$30M$0$0
Investment Purchases-$15M-$23M-$46M-$41M-$310M
Investment Sales$0$37M$59M$25M$328M
Other Investing$0-$37M$0-$6M$448K
Investing Cash Flow-$16M-$37M-$17M-$22M$18M
— Financing Activities —
Net Debt Issuance-$38M$13M$26M$16M$0
Stock Repurchased-$3M-$5M-$3M$0$0
Dividends Paid$0$0$0$0$0
Other Financing$105M$291K$6M$1M-$372K
Financing Cash Flow$113M$8M$28M$82M$12M
Net Change in Cash$108M-$47M-$22M-$9M$29M
Cash End of Period$112M$65M$43M$34M$62M
Free Cash Flow$10M-$19M-$34M-$70M-$2M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms